BACKGROUND: Acute pain services have received widespread acceptance and formal support from institutions and organizations, but available evidence on their costs and benefits is scarce. Although there is good agreement on the provision of acute pain services after many major surgical procedures, there are other procedures for which the benefits are unclear. Data are required to justify any expansion of acute pain services. In this randomized, controlled clinical trial we compared the costs and effects of acute pain service care on clinical outcomes with conventional pain management on the ward. Patients included in the trial were considered by their anesthesiologist to have either arm be suitable for the procedure. METHODS: Four hundred twenty-three patients undergoing major elective surgery were randomized either to an anesthesiologist-led, nurse-based acute pain service group with patientcontrolled analgesia or to a control group with IM or IV boluses of opioid analgesia. Both groups were treated with medications to treat opioid-related adverse effects and received the usual care from health professionals assigned to the ward. The main outcome measures were quality of recovery scores, pain intensity measures, global measure of treatment effectiveness, and overall pain treatment cost. Cost-effectiveness acceptability curves were drawn to detect a difference in the joint cost-effect relationship between groups. RESULTS: There was no difference in quality of recovery score on postoperative day 1 between treatment and control groups (mean difference, 0; 95% confidence interval [CI], Ϫ0.7 to 0.7; P ϭ 0.94) or in the rate of improvement in quality of recovery score (mean difference, Ϫ0.1; 95% CI, Ϫ0.4 to 0.1; P ϭ 0.34). The proportion of patients with 1 or more days of highly effective pain management was higher in the acute pain service group than in the control group (86% vs. 75%; P Ͻ 0.01). Costs were higher in the acute pain service group (mean difference, US$46; 95% CI, $44 to $48 per patient; P Ͻ 0.001). A cost-effectiveness acceptability curve showed that the acute pain service was more cost effective than was control for providing highly effective pain management if the decision maker was willing to pay more than US$546 per patient per 1 day with highly effective treatment. CONCLUSION: In extending the role of the acute pain service to a specific group of major surgical procedures, the acute pain service was likely to be cost effective.
may be because of new surgical techniques that may decrease postoperative pain (laparoscopic assisted procedures), or patients expected to have significant postoperative pain but had not been offered APS in the past (e.g., cardiac surgery). Although all anesthesiologists would consider using APS in these patients, mixed views were held by staff on the desirability and necessity of providing APS for them. Thus, data are required to justify any expansion of acute pain services to these patients. Because they had not traditionally been receiving APS, it was possible to randomize these patients to APS or standard ward care.
Therefore, we performed prospective cost-effectiveness analyses alongside a randomized controlled trial of APS care versus conventional pain management on the ward in patients undergoing major elective surgery, for whom the attending anesthesiologist was uncertain about the benefits of APS care. Our objective was to compare the costs and effects of APS care on clinical outcomes with conventional pain management on the ward in patients undergoing major elective surgery from the perspective of the Hospital Authority (a government body funding public health services in Hong Kong).
METHODS
The study was conducted at the Prince of Wales Hospital in Hong Kong, a large university teaching hospital. The study was approved by the local Clinical Research Ethics Committee. The study was registered in the Centre for Clinical Trials Clinical Registry of The Chinese University of Hong Kong (trial no. CUHK_CCT00105) on February 28, 2006 , available at http://www.cct.cuhk.edu.hk/registry/publictriallist.aspx. After giving written informed consent, adult patients were enrolled from April 8, 2006 , to February 12, 2009 . The APS is staffed by 2.2 anesthesiologists and 1 nurse full-time equivalent to provide the service continuously 24 h/day, serving an average of 17 patients per day (unpublished data for 2009).
Patients
Groups of patients were identified that could possibly benefit from APS, but for whom APS care was not often used in the past. Inclusion criteria were adults, ages 18 years or older and undergoing major surgery (such as laparoscopic hemicolectomy, open reduction and internal fixation, total abdominal hysterectomy) or complex major surgery (e.g., coronary artery bypass graft, discectomy) as is defined by the Hong Kong Government Gazette. 10 Patients recruited to this study were only those identified by the attending anesthesiologist as being candidates who may or may not benefit from APS, in comparison with conventional ward pain service (CWPS). All patients had general anesthesia with no additional regional anesthesia. Patients were excluded if they were younger than 18 years of age, undergoing emergency or obstetric surgery, had a history of cognitive impairment or preoperative opioid use, or were unable to give consent.
The principal investigator (Anna Lee) generated the random allocation sequence using a computer and was not involved in the data collection process. Two investigators (Angel S. C. Lau, and Chun Hung Chiu) were responsible for randomizing eligible patients within 24 hours of meeting the study criteria to either APS or CWPS care, by using a sealed opaque envelope containing a computer-generated random treatment allocation.
Treatment Procedures
Patients randomized to the APS group received IV morphine PCA with or without supplementary oral analgesics, and medications to treat opioid-related adverse effects. They were seen by an APS nurse or an anesthesiologist or both once daily (normal practice). The APS team was informed if any of the following occurred: inadequate pain control (persistent pain score Ն3 of 10), oxygen desaturation (Spo 2 Ͻ90%), bradypnoea (respiratory rate Ͻ10/min), hypotension (systolic blood pressure Ͻ90 mm Hg), uncontrolled nausea and vomiting with parenteral antiemetic, severe pruritus if uncontrolled with chlorpheniramine 5 mg q8h prn IM/IV, or difficulty awakening the patient. Although APS did offer acute pain techniques such as peripheral nerve blocks and epidural PCA, these techniques were not used in this study. Patients randomized to the CWPS group received opioid (pethidine, morphine, tramadol), nonopioid (diclofenac, paracetamol/phenyltoloxamine, paracetamol) analgesics by IM, IV boluses and/or oral routes, and medications to treat opioid-related adverse effects prescribed by surgeons. All patients received the usual care from surgeons and nursing professionals assigned to the surgical ward (and intensive care unit for postoperative care if undergoing coronary artery bypass graft). The patient, attending health professionals, and research staff were not blinded to the treatment assignment.
Data Collection
All surgical patients were admitted as inpatients on the day before surgery. Patients were interviewed by an investigator (Angel S. C. Lau or Chun Hung Chiu) on 3 consecutive days after their surgery with a standardized questionnaire. We collected data on patient's demographics, ASA Physical Status, and length of hospital stay. We measured pain intensity (worse pain, average pain in the last 24 hours, and current pain), pain at rest, pain during movement and pain interference with daily activities (walking ability, mood, sleep, relations with others, and ability to concentrate), and ratings on a numeric rating scale (NRS) using the modified Brief Pain Inventory questionnaire 11 on days 1 to 3 after surgery. A global measure of treatment effectiveness was measured by asking patients, "How effective do you think the treatment for pain was?" using a 5-point Likert scale (0 ϭ poor, 1 ϭ fair, 2 ϭ good, 3 ϭ very good, 4 ϭ excellent).
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The 9-item Quality of Recovery (QOR) score 13 was collected to measure the patient's health-related quality of life after anesthesia and surgery on a daily basis with a score from 0 to 18. The frequency, severity, and distress of opioid-related side effects (nausea, vomiting, difficulty in concentrating, drowsiness or difficulty staying awake, feeling confused, and feeling of general fatigue or weakness) were totaled daily into an adverse effect score (from 0 to 60). These specific symptoms from the opioid-related symptom distress scale 14 were chosen because they were thought to have a negative effect on patient's daily activities and recovery after surgery.
All calculated direct costs related to postoperative pain management were based on the first 3 days after surgery. From the patient's drug chart, we recorded the type, dose, and frequency of analgesic drugs and the drugs used to treat opioid-related side effects. The medication costs were estimated from the unit costs of the hospital pharmacy. The PCA costs, obtained from the hospital administration, included the cost for infusion pump, IV tubing sets, cartridges, catheters, batteries, syringes, needles, swabs, dressings, saline, and morphine. From the patient's APS record, the staff cost was calculated using the total nursing and anesthesiologist time spent for each patient. The nursing and anesthesiologists' staff salaries, obtained from the hospital administration, were based on the midpoint of the relevant pay scale. The ward nursing cost for APS and CWPS groups were assumed to be the same as a previous study at our hospital, 15 showing that there was no significant difference in total ward nursing time (communication, documentation, administration of drug, and observations) for patients receiving PCA or IM opioid injection. The total postoperative pain management cost was a total of the costs for analgesic drugs, drugs to treat opioid-related side effects, PCA, and APS staffing. At the time of reporting the study results (October 31, 2009), 1 US$ ϭ HK$7.75. All costs are reported in U.S. dollars.
Outcome Measures
The primary outcome measure was QOR scores. Pain intensity (mean pain ratings for worst pain, average pain in the last 24 hours, and current pain), pain intensity at rest, pain intensity during movement, global measure of treatment effectiveness, and overall pain treatment cost outcomes were also measured. These outcome measures were used in defining the incremental cost-effectiveness ratios and incremental net benefits, the appropriate measures of reporting results from a cost-effectiveness analysis. 16 Specifically, the effectiveness of the intervention for costeffectiveness analysis purposes was expressed as the number of pain-free days at rest, 17 pain-free days with movement, 17 and days with highly effective treatment. A pain-free day was defined as having a NRS Յ3 on a 0 to 10 scale. The analgesic effectiveness was 3 if the patient had 3 pain-free days, and 0 if the patient did not experience NRS Յ3 at all. The number of days with highly effective treatment was 3 if the patient rated his or her global measure of effectiveness as excellent or very good on all 3 days, and 0 if the patient did not have days with excellent or very good ratings.
Other secondary end points included pain interference during daily activities, adverse effect score, in-hospital mortality, and length of hospital stay. A pain-free interference day was defined as having a mean NRS of 0 with pain interference on daily activities scales ranging from 0 to 10. The interference-free effect was 3 if the patient had 3 pain-free interference days, and 0 if the patient experienced pain that interfered with daily activities on all 3 days. The length of stay was not included in the cost-effectiveness analysis because we believed that it was a weak outcome measure. The delay in patient discharge from hospital was often not due to pain or analgesia-related side effects but due to postoperative rehabilitation plans, level of social support, and surgeon's postoperative treatment preferences.
Statistical Analysis
We calculated the sample size using QOR as the primary outcome because this was a more patient-centered outcome than were pain ratings and cost. We calculated that a sample size of 522 would provide 80% power to detect a small to moderate effect size (0.25) between groups using a 2-sample t test (EAST 5.2, Cytel Software Corporation, Cambridge, Massachusetts), allowing for interim analyses. Two interim analyses were planned after 174 and 348 patients had completed their participation in the study using the O'Brien-Fleming stopping rules, with ad priori boundaries of P Յ 0.0002 and P Յ 0.0121 to reject the null hypothesis (efficacy boundary, if large treatment differences appear before the end of the study), and P Ն 0.9659 and P Ն 0.3444 to accept the null hypothesis (futility boundary, if there is little chance of finding a significant difference between groups).
The primary analyses were performed on a modified intention-to-treat basis (i.e., patients were analyzed according to their randomized allocated groups but were excluded from the analysis if they did not adequately adhere to the protocol after randomization.). We used the 2-sample t test, 2 test, Fisher exact test, and Mann-Whitney U test to compare baseline characteristics. The mean difference is defined as the APS outcome measure minus CWPS outcome measure. For the QOR, pain intensity and interference outcomes, global measure of effectiveness, and adverse effect score, we used multilevel regression models 18, 19 to assess the intervention effect on the change between the measurements taken on the first to third day after surgery. An advantage of using a multilevel regression model over a repeated-measure analysis of variance is that it can account for complex covariance structure and accommodate incomplete data. 19 Given the expected large variability of cost data, the study was underpowered to test the economic hypothesis that APS would be more cost effective than would CWPS. However, in the absence of sufficient power to test the economic hypotheses, there have been methodological advances in examining sampling uncertainty for incremental cost-effectiveness ratios, with emphasis on the likelihood that the intervention represents good value for the cost rather than on economic hypothesis testing. 20, 21 We assumed that APS was cost effective if the extra cost of an extra gain in effect was less than the decision maker's willingness to pay (WTP) for it. 22 For example, if the maximum WTP was set at $200, APS would be cost effective if the incremental cost-effectiveness ratio (ratio of the extra cost to extra benefit, i.e., ⌬C/⌬E) was less than $200. The 95% confidence interval (95% CI) around the incremental cost-effectiveness ratio was estimated using the Fieller method. Because there is uncertainty on the WTP value and the true estimate of the incremental costeffectiveness ratio, the cost-effectiveness acceptability curve was constructed from net benefit (NB) regressions. 23 Under the NB framework, each subject's NB is computed from the observed data as WTP ϫ effect i Ϫ cost i , where effect i and cost i are the data for the ith person's effect and cost, respectively, and WTP is a willingness-to-pay number that must be specified. 24 In its simplest form, the NB regression involves fitting the following linear regression model:
where TX i is the ith person's treatment indicator (TX i ϭ 1 for APS and 0 for CWPS) and i is a stochastic error term. 24 The equation is fitted several times, each time with a different value of WTP value. 24 To generate a cost-effectiveness acceptability curve, we used the probability that ␤ TX Ͼ0 for the y axis and WTP for the x axis. 24 In other words, the costacceptability curves showed the probability that APS was more cost effective than was CWPS for a range of values that decision makers might be willing to pay for 1 day gained of beneficial effect. All analyses were performed with STATA software version 10.0 (StataCorp, College Station, Texas), and cost-effectiveness analysis was performed using the macro "iprogs" available from the University of Pennsylvania (www.uphs.upenn.edu/dgimhsr/stat-cicer.htm; accessed April 28, 2010). A 2-sided P Ͻ 0.05 was considered statistically significant. We declared the trial to be positive if more than 1 of the outcomes, but not all, were significant after correcting for multiplicity using the Holm stepwise approach (corrected overall critical P value was 0.0167). 25 
RESULTS
The trial was stopped at the second interim analysis, after 402 patients had completed the study, on the basis of slower-thananticipated accrual rate and a prespecified futility stopping rule. On the basis of 398 patients who had complete day 1 QOR data (195 in the APS group and 203 in the CWPS group), comparison of the day 1 QOR via a 2-sample t test (P ϭ 0.43) crossed the a priori futility boundary for early stopping with acceptance of the null hypothesis of no difference between groups. At interim analysis, it was calculated that if the study had continued to the planned enrollment of 522, the probability of demonstrating a difference in day 1 QOR between treatment groups was Ͻ1% under the alternative hypothesis on the basis of the observed unadjusted day 1 QOR treatment group differences.
Study Population
Of the 470 surgical patients screened for the study, 422 met the study criteria and were randomized. Two hundred nine patients were allocated to the APS group, and 213 to the CWPS group (Fig. 1) . Ten patients from each group withdrew from the study after randomization. Although the gender and type of surgery distributions in the withdrawal group were similar to those of patients who completed the study (Fisher exact test P ϭ 1.00 and 2 test P ϭ 0.16, respectively), the patients who withdrew were older than those who completed the study (mean [SD], 58 [8] for those who withdrew and 52 [12] for those who completed; 2-sample t test P ϭ 0.02). The baseline characteristics at enrollment were similar for age, gender, type and magnitude of surgery, ASA Physical Status, and length of stay in the intensive care unit between APS and CWPS patients ( 
Outcomes
The point estimates on the first day after surgery and the mean change over 3 days for QOR, pain intensity, interference with daily activity from pain, global measure of treatment effectiveness, and adverse effect outcomes are shown in Table 2 . There were no differences between groups for outcomes on the first day of surgery: QOR (P ϭ 0.94), pain intensity (P ϭ 0.31), and pain on movement (P ϭ 0.17). However, APS patients had lower pain scores at rest, less interference with daily activities because of pain, and better treatment effectiveness than did CWPS patients on the first day after surgery ( Table 2 ). The rate of improvement in QOR scores (P ϭ 0.34), daily rate reductions in pain intensity (P ϭ 0.20), and pain during movement (P ϭ 0.07) between the 2 groups were similar. The APS group had significantly smaller daily reductions in pain scores at rest and interference with daily activities than did the CWPS group over the first 3 days after surgery ( Table 2) .
The incidence of moderate to severe pain (NRS Ͼ3 on a 0 to 10 scale) at rest and on movement after major surgery in the 2 groups is shown in Table 3 . The incidences of "poor" treatment effectiveness on the first day after surgery in the APS and CWPS groups were 0.5% (95% CI, 0.1 to 2.9) and 4.8% (95% CI, 2.5 to 8.8), respectively. The proportion of patients with 1 or more days of highly effective pain management (i.e., treatment effectiveness rated as very good and excellent) was higher in the APS group than in the control group (86% vs. 75%; absolute risk difference 11%; 95% CI, 3% to 20%; 2 test P Ͻ 0.01; Fig. 2 ). This is equivalent to a number needed to treat of 9 (95% CI, 5 to 33). There were no significant 
Adverse Events
One patient in the APS group had respiratory depression due to PCA with morphine (incidence 0.5%, 95% CI, 0.1% to 2.8%) and required IV 0.8 mg naloxone treatment. During the study, 1 patient in the APS group died after coronary artery bypass surgery in the intensive care unit because of uncontrolled bleeding from the surgical site. The risk of opioid-related side effects at any time during the follow-up was similar between groups (41% in the APS group and 40% in the CWPS group; absolute risk difference 1%, 95% CI, Ϫ9% to 12%; 2 test P ϭ 0.76). However, the severity of opioid-related side effects on the first day after surgery tended to be less in the APS group than in the CWPS group (Table 2 ; P ϭ 0.06). Overall, both groups experienced 1 day of no opioid-related side effects (Table 4) .
Costs
As was expected, the costs of analgesia, medications to treat opioid-related side effects, and APS staff costs were significantly higher in the APS group than in the CWPS group (Table 5 ). The mean difference in the total cost of pain treatment was US$46 (95% CI, $44 to $48) per patient (P Ͻ 0.001). Because there was no significant extra day gained for being pain free at rest, pain free during movement, no opioid-related side effects, and no interference with daily activity measures in the APS group over the CWPS group, incremental cost-effectiveness ratios were not estimated. The incremental cost-effectiveness ratio for costs per 1 day with highly effective treatment gained was US$151 (95% CI, $87 to $546) per patient. Decision makers who are willing to pay less than US$87 per patient per 1 day with highly effective treatment can be 95% confident that the APS represents bad value; between US$87 and US$546 per patient per 1 day with highly effective treatment, the decision maker cannot be 95% confident that the 2 interventions differ in value; for those willing to pay more than US$546 per patient per 1 day with highly effective treatment, they can be 95% confident that the APS represents good value in comparison with CWPS (Fig. 3) .
DISCUSSION
We conducted a cost-effectiveness analysis alongside a randomized controlled trial of APS versus CWPS. Previous studies included in systematic reviews 7, 27, 28 examining the effect of APS on postoperative outcomes were likely to be biased because the studies were observational in design (before-after studies, matched comparisons). In this trial of 422 patients, there were no significant differences in the Figure 2 . The number of days experiencing a highly effective treatment ("very good" and "excellent" ratings) in the acute pain service and conventional ward pain service groups. There was a significant difference between the 2 groups (P Ͻ 0.01). a One patient in the acute pain service group did not receive the intervention because of lack of staff to set up the IV patient-controlled analgesia in the recovery room. Three patients in the conventional ward pain service group received acute pain service intervention after initial pain treatment was inadequate. Refer to METHODS section in text for costing methodology.
QOR score on the first day after surgery or in the rate of improvement in the QOR score between the 2 groups. It is possible that the 9-item QOR instrument lacked responsiveness and discrimination when compared with the 40-item QOR instrument. 29 Nevertheless, we found lower pain scores at rest, less interference with daily activities because of pain, and better global measure of treatment effectiveness for the APS group on the first day after surgery. These results suggest that there are some initial benefits associated with APS over CWPS in the early postoperative period, but that they disappear on the second and third day after surgery. Although we did not measure patients' locus of control in pain, we believe that PCA afforded greater perceived control over pain relief 30 and that this benefit extended past the first day after surgery. Not surprisingly, APS was associated with additional costs, mainly from staff costs, which were 57% of the total cost of pain treatment.
Although up to one third of patients in this trial experienced moderate to severe pain at rest on the first day after surgery, the mean difference in pain at rest scores (Ϫ0.9, 95% CI, Ϫ1.4 to Ϫ0.3) between groups was statistically and clinically significant (28% reduction) if one considers a 20% reduction to represent a minimum clinically important difference. 31 Half of our patients experienced moderate to severe pain during movement on the first day after surgery. This incidence appears to be high in comparison with the results of a meta-analysis of 33 studies by Dolin et al. (95% CI, 25% to 40%). 2 We found differences between the 2 groups for pain at rest, but not pain during movement on the first day after surgery. These conflicting findings may suggest that many patients are unable to distinguish between pain at rest and pain during movement, because this may be influenced by coughing, need for physiotherapy, and dressing changes.
2 Therefore, our results for pain during movement require cautious interpretation.
Pain interference with daily activities-such as walking ability, mood, sleep, relations with others, and ability to concentrate-are increasingly being used in conjunction with pain intensity outcomes. This outcome represents the physical and mental functions affected by pain during the recovery process from anesthesia and surgery. We showed that APS was associated with less pain interference on daily activities on the first day of surgery, but this effect over subsequent days was less than that in the CWPS group and made no difference to the quality of recovery.
During the trial, 1 patient died from surgical complications. The risk of respiratory depression associated with PCA in the APS group (0.5%) was similar to that reported in Werner et al.'s systematic review. 27 We found no evidence to support APS in preventing or reducing the incidence of opioid-related side effects. However, in comparison with the CWPS group, there was some weak evidence to suggest that APS was associated with milder opioid-related side effects.
We used a global measure of treatment effectiveness outcome for our cost-effectiveness analysis. The global measure of treatment effectiveness allows patients to balance the unpleasantness or inconvenience of the pain service intervention, the personal meaningfulness of improvements in pain and function, and the unpleasantness and meaning of any opioid-related side effects. 8 We showed that for every 9 patients treated with the APS, 1 would experience 1 or more days of highly effective pain treatment. A previous study 12 showed that the global measure of treatment effectiveness is valid and can provide estimates of analgesic efficacy equivalent to pain relief.
When interpreting whether APS is cost effective, it is important to ask how much decision makers are willing to pay for APS to be highly effective rather than spend funds on improving analgesic techniques per se for being pain free at rest or during movement. Our trial suggests that we can be certain that APS is cost effective when the WTP for an extra day gained from a highly effective treatment was more than US$546 per patient. This estimate is higher than the value of what Ͼ90% of Canadian patients were willing to pay, which was no more than US$245* for APS to provide PCA treatment. 32 The differences in results may be due to differences in median household income, patient population, and the WTP methodology. It is likely that our anesthesiologist-led nurse-based APS is cost effective because funding of APS reflects public preferences for acute pain relief and perceived aversion to major complications related to inadequate pain relief. 33, 34 This study has several limitations that need to be considered. We expanded the coverage of APS care to a specific group of major surgical procedures for which the benefits of PCA were uncertain. The IV PCA mode accounted for 92% of the pain techniques given by the APS in 2009 at our hospital. It could be argued that this study compared IV PCA to IM analgesia, rather than a comparison between APS and CWPS care. However, we believe that our study is the latter because we chose to focus on the health service infrastructure providing the postoperative pain management rather than the pain technique per se.
In the design of economic analysis alongside clinical trials, it is recommended that the study should be more naturalistic to increase the external validity of the economic results for which the objective is to determine the value for Cost-effectiveness acceptability curve showing the probability that acute pain service (APS) is cost effective for a range of decision makers' maximum willingness to pay (U.S. dollars) for 1 day with highly effective treatment gained. The observed mean incremental costeffectiveness ratio of US$151 per patient (x axis) corresponds to a 50% probability of the acute pain service being cost effective (y axis).
Cost Effectiveness of Acute Pain Service money (i.e., lowest cost per unit benefit). 20, 35 That is, pragmatic trials evaluate effectiveness in comparison with standard care in "real-world" patient populations and practice settings, and although internal validity may be lower than a standard randomized controlled trial, they are more suitable for collection of health economic data. 20, 35 Although PCA is a common device used by APS, many patients (63%) who are not cared for by an anesthesiologstbased service also receive PCA. 6 Given the same availability of oral/IM analgesia and PCA technology, a dedicated APS will prescribe and use these pain techniques differently than will non-APS physicians. 36 For example, if surgeons prescribed a regular parenteral opioid to patients on the first day after surgery, we would expect pain relief outcomes to be similar to those of the APS group. However, because there were significant differences in pain outcomes between the groups on the first day after surgery, it is likely that patients were prescribed PRN analgesia in the CWPS group. Although surgeons want to maintain an active role in postoperative pain management, 37 extending the role of APS is likely to be more cost effective than the CWPS by surgeons.
The results of this trial are not generalizable to different organizational structures of APS. Our APS is an anesthesiologist-led, nurse-based model that is the typical model found in Hong Kong and Australian hospitals. In many centers, the anesthesiologist in the APS may only attend ward rounds once or twice a week, with most care given by nurses who specialize in pain medicine. This would likely reduce the staffing costs associated with an anesthesiologist-led, nurse-based APS program. An economic analysis of a nursed-based APS 33 concluded that it was cost effective. However, we believe that there is still uncertainty about its cost effectiveness given that a costeffectiveness acceptability curve was not drawn. We estimate that, if we changed our APS model to a nurse-based APS, we would reduce the overall pain cost by 25%. However, we are uncertain about what corresponding changes in clinical benefits would arise.
The nature of the pain service intervention meant that patients, health care professionals and the research assistants could not be blinded. Therefore, we cannot exclude the possibility of measurement bias and the Hawthorne effect of the APS visits in this trial. However, we believe that selection bias and confounding would be minimal in this randomized controlled trial. Because the pain score measured every 4 hours was not part of routine postoperative care on the ward at the time of the study, we collected the daily pain scores from patients; however, this may be prone to recall bias. We used multiple primary outcomes measures to adequately capture the complexity of the pain experience and how it may be modified by pain management interventions consistent with best practices in pain research. 8 Furthermore, we minimized the risk of making a false positive conclusion about the clinical benefits of APS using methods recommended by the IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials) guidelines. 25 Improving postoperative pain management by the use of APS remains a public health challenge. 38 Many APS face structural, political, cultural, educational, emotional, and physical/technological challenges despite considerable efforts by APS members. 38 Many surgeons are satisfied with the service provided by the APS but many want to maintain an active role in postoperative pain management. 37 We have shown that the anesthesiologist-led, nurse-based APS is likely to be more cost effective than is the CWPS.
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